Introduction
============

Recent advances in the biology of non-small cell lung cancer (NSCLC) have identified driver mutations that can predict response to the therapy. This molecularly targeted therapy has dramatically improved results for patients whose tumors harbor somatically activated oncogenes, such as epidermal growth factor receptor (*EGFR*), anaplastic lymphoma receptor tyrosine kinase (*ALK*), ret proto-oncogene (*RET*) or ROS proto-oncogene 1 (*ROS1*) ([@b1-ol-0-0-4788]--[@b3-ol-0-0-4788]). Although *EGFR* mutations and *ALK*, *RET* and *ROS1* translocations are predominantly detected in lung adenocarcinomas from never-smokers and light smokers, these associations are not absolute; thus, clinical profile must not be used to exclude patients from molecular testing for specific alterations ([@b4-ol-0-0-4788]).

Activating rearrangements of *ALK* gene are detectable in 1.9--6.8% of NSCLC cases ([@b5-ol-0-0-4788]--[@b9-ol-0-0-4788]). In these tumors, a fusion gene involving echinoderm microtubule associated protein-like 4 (*EML4*) and *ALK* (*EML4-ALK*) encodes a chimeric protein with constitutive tyrosine kinase activity that confers transformation potential and responsiveness to specific targeted inhibitors ([@b5-ol-0-0-4788]). Whereas the fused *ALK* gene region remains constant (exon 20), different *EML4* exons can be affected, generating several variants; other *ALK* fusion partners have also been reported ([@b10-ol-0-0-4788],[@b11-ol-0-0-4788]). In patients with *ALK*-positive NSCLC, the use of crizotinib, an oral ATP-competitive selective inhibitor of the *ALK* tyrosine kinase, along with a new generation of *ALK* tyrosine kinase inhibitors (alectinib and ceritinib), has demonstrated superiority over standard chemotherapy ([@b3-ol-0-0-4788],[@b4-ol-0-0-4788]).

Fluorescence *in situ* hybridization (FISH), bright-field dual-color chromogenic *in situ* hybridization ([@b12-ol-0-0-4788]), immunohistochemistry (IHC) ([@b7-ol-0-0-4788],[@b12-ol-0-0-4788]) and reverse transcriptase-polymerase chain reaction ([@b13-ol-0-0-4788]) are available methods for the detection of *ALK* rearrangements. *ALK* FISH has been recognized as the most sensitive method ([@b9-ol-0-0-4788]). Recently, the FDA has approved the Ventana ALK (D5F3) CDx Assay (Roche, Tucson, AZ, USA) to identify patients for crizotinib therapy. Ultrasensitive IHC assays may obviate FISH confirmation in positive IHC cases; however, the likelihood of false negative IHC results demands FISH testing, at least in some situations ([@b7-ol-0-0-4788],[@b8-ol-0-0-4788],[@b12-ol-0-0-4788]). Currently, the only approved FISH assay for the detection of *ALK* positivity, as a companion diagnostic tool for crizotinib-based treatment eligibility, is the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular, Des Plaines, IL, USA).

In the current study, we describe our experience of FISH *ALK* rearrangement detection in 2,045 routine diagnostic samples in the public health care system of Galicia (Spain). This report is of particular interest for comparative purposes due to Galicia\'s isolation in North-Western Spain and its specific cultural characteristics, which may contribute to the emergence of genetic diversity ([@b14-ol-0-0-4788]).

Materials and methods
=====================

### Patients and samples

A total of 2,045 unselected samples of NSCLC from patients in 9 hospitals of the Galician public health care system (Spain), collected between October 2010 and July 2015, were investigated. Samples were received as buffered formalin-fixed, paraffin-embedded tissue biopsies, cell blocks and cytological smears. In the referral center (Clinical University Hospital, Santiago de Compostela, Spain), pathologists verified the adequacy of the samples and reviewed the diagnosis according to the World Health Organization criteria ([@b1-ol-0-0-4788]). For all patients, medical records were reviewed, and written informed consent obtained. The Independent Ethics Committee of Galicia (Galician Healthcare Service; SERGAS) approved the study protocol, which was conducted in accordance with the Declaration of Helsinki and applicable Spanish laws.

### ALK FISH analysis

The *ALK* genetic status of each patient was evaluated by FISH in representative tumor areas, with an LSI *ALK* dual-color, break-apart rearrangement probe (Vysis *ALK* Break Apart FISH Probe Kit, Abbott Molecular Inc.), following the manufacturer\'s protocol. In each case, 50 non-overlapping nuclei were examined by fluorescence microscope (BX51; Olympus Corporation, Barcelona, Spain). The kit included red (3′) and green (5′) break-apart probes. *ALK* was determined to be not rearranged when the two signals were adjacent or fused (appearing yellow under an Orange/Green V2 filter) or when there was a single green signal. *ALK* was considered positive (rearranged) when ≥1 set of red and green signals were ≥2 signal diameters apart, or when a single red signal was present. A sample was considered negative for *ALK* if \<5 cells out of 50 (\<10%), and positive when \>25 cells out of 50 (\>50%), exhibited split *ALK* 5′ and 3′ probe signals or isolated 3′ signals. With borderline results, when the number of positive cells was 5--25 (10--50%), a second reader evaluated the slide: First and second cell count readings were added together and a percentage out of 100 cells was calculated. If the positive cell percentage was ≥15%, the sample was considered positive.

### Statistical analysis

Statistical analysis was conducted with SPSS version 19.0 (IBM SPSS, Armonk, NY, USA). The association between *ALK* mutation status and clinicopathological features was calculated using Pearson\'s χ^2^ test or Fisher\'s exact test. P\<0.05 was considered to indicated a statistically significant difference.

Results
=======

### ALK assessment

The 2,045 samples of NSCLC included 1,686 (82.4%) tissue biopsies, 306 (15%) cell block samples and 53 (2.6%) cytological smears. Among the total samples examined, 1,866 (91.2%) could be tested by FISH ([Fig. 1](#f1-ol-0-0-4788){ref-type="fig"}). Specifically, 1,566 (92.9%) tissue biopsies, 256 (83.7%) cell blocks and 46 (86.8%) cytological smears could be assessed. In the remaining 179 (8.8%) samples, the FISH result was not obtained owing to insufficient/non-representative tumor material (n=143; 79.9%) or to assay failure (n=36; 20.1%) due to pre-analytical factors (poor fixation, decalcification treatment, etc.). The rate of successful evaluation was not significantly higher in histological samples compared with cytological samples (92.9% vs. 84.1%). Additionally, no differences were found between cell blocks and cytological smears (83.7% vs. 86.8%).

### ALK rearrangement

*ALK* rearrangements were identified in 82 (4%) out of 2,045 tumor samples: 65 (79.3%) tissue biopsies, 15 (18.3%) cell blocks and 2 (2.4%) cytological smears ([Table I](#tI-ol-0-0-4788){ref-type="table"}). The mean percentage of *ALK*-positive cells was 52% (range, 15--92%). A typical translocation pattern was observed in 62 (75.6%) cases, and the remaining cases (24.4%) exhibited a split pattern ([Fig. 1](#f1-ol-0-0-4788){ref-type="fig"}).

### Clinicopathological findings

The clinicopathological features of the 2,045 NSCLC patients are summarized in [Table I](#tI-ol-0-0-4788){ref-type="table"}. The majority were male (69.4%) and ex-smokers (38.3%) or current smokers (37.2%). At diagnosis, the vast majority were in advanced stage (43.2% at stage IV). The predominant histological type was adenocarcinoma (76.2%). Significant associations between *ALK* rearrangement and younger age (P\<0.001; Mann-Whitney U test), female gender (P\<0.001; Pearson\'s χ^2^ test), non-smoking history (P\<0.001; likelihood ratio test), stage IV at diagnosis (P\<0.001; likelihood ratio test) and the adenocarcinoma histological type (P=0.046; likelihood ratio test) were found. Other *ALK*-positive tumor types were large cell neuroendocrine carcinomas (n=2), squamous carcinoma (n=1) and not otherwise specified carcinomas (n=7). *ALK*-positive adenocarcinomas (n=72) exhibited a predominantly solid pattern of growth in 45.8% of cases, with cellular features of signet ring cell carcinoma in 36.4% (n=12) of these ([Table II](#tII-ol-0-0-4788){ref-type="table"} and [Fig. 2](#f2-ol-0-0-4788){ref-type="fig"}). No simultaneous *EGFR* mutations were detected in any cases.

Discussion
==========

To the best of our knowledge, this is the largest study on *ALK* rearrangements in unselected NSCLC patients in a Spanish Caucasian population. It is also the first study in Galicia, North-Western Spain, and is particularly interesting as the adequacy and histology of all samples were reviewed in a single institution by the same pathologists using the same criteria. Although Galicia is relatively isolated, the current results confirm the low frequency of *ALK* rearrangements (4%) in unselected Caucasian NSCLC patients, which is marginally higher than values from other areas of Spain (3%) ([@b6-ol-0-0-4788]), and within the range of 1.9--6.8% reported in the literature ([@b5-ol-0-0-4788],[@b7-ol-0-0-4788]--[@b9-ol-0-0-4788]).

The current study utilized the Food and Drug Administration (FDA)-approved *ALK* break-apart FISH method, with excellent results. The successful evaluation rate difference between tissue samples and cytological samples was not significant (92.9% vs. 84.1%); very similar results were obtained using cell blocks and cytological smears (83.7% vs. 86.8%). Although technical limitations have been reported in cytological specimens ([@b6-ol-0-0-4788]), the success rate in the present study was in line with the literature, which reports the feasibility of *ALK* FISH analysis of cytological samples as ranging from 79--97% ([@b15-ol-0-0-4788]). Cytological smears may be preferable for FISH assays as they avoid formalin fixation problems and permit the evaluation of whole nuclei, eliminating overlapping nuclei and nuclear truncation ([@b16-ol-0-0-4788]). According to FDA guidelines ([@b12-ol-0-0-4788]), this FISH analysis is applicable on histological samples, however, cytological smears could also be appropriate.

The present study revealed an apparent association of *ALK* rearrangement with non-smoking, female gender, younger age, stage IV and adenocarcinoma. The significant proportion of *ALK*-positive non-smokers is consistent with previous reports ([@b9-ol-0-0-4788]), but 55.9% of the current cases were previous or current smokers, which confirms that smoking is not a reliable criterion on which to predict or exclude *ALK* rearrangement. *ALK* positivity was determined to be strongly associated with female gender (P\<0.001); however, controversial results have been reported ([@b6-ol-0-0-4788],[@b8-ol-0-0-4788]). A marginally, non-significantly higher rate of *ALK* positivity in females has been described in a recent meta-analysis of 6,950 patients ([@b9-ol-0-0-4788]). The results of the present study and that of Proietti *et al* ([@b16-ol-0-0-4788]) found a younger age to be associated with *ALK* rearrangement. We also found *ALK* positivity to be associated with stage IV disease; however, analysis of a greater number of patients in other stages would be desirable to reach reliable conclusions. Consistently with previous reports ([@b6-ol-0-0-4788],[@b8-ol-0-0-4788],[@b9-ol-0-0-4788]), the current results found *ALK* rearrangements to be largely, but not completely, restricted to adenocarcinomas, specifically solid or acinar variants or with signet ring cell features. *ALK* positivity was also identified in one squamous cell carcinoma and two large cell neuroendocrine carcinomas.

In conclusion, the present findings indicated that ALK evaluation by FISH is feasible in tissue and cytological samples. It was also found that ALK translocation is associated with a non-smoking history, a younger age, the female gender, stage IV and the adenocarcinoma histological type. Due to the fact that ALK rearrangement was detected in various histological tumor types, the ALK study should not be restricted to adenocarcinomas.

![*ALK* break-apart FISH signals in non-small cell lung cancer. (A) *ALK* FISH-negative specimen. (B) *ALK* FISH-positive specimen showing split red and green signals. (C) *ALK* FISH-positive specimen showing isolated single red signals. *ALK*, anaplastic lymphoma receptor tyrosine kinase; FISH, fluorescence *in situ* hybridization.](ol-12-02-1403-g00){#f1-ol-0-0-4788}

![Representative histological patterns of adenocarcinoma tissues. (A) Solid growth pattern, (B) solid pattern with a signet ring cell component, (C) acinar pattern, (D) cribriform pattern, (E) mucinous pattern, and (F) micropapillary pattern. Hematoxylin-eosin staining; original magnification, ×400.](ol-12-02-1403-g01){#f2-ol-0-0-4788}

###### 

Clinical and pathological features of patients positive and negative for *ALK* rearrangement.

  Variable                                                              All cases      *ALK*-negative cases   *ALK*-positive cases   P-value
  --------------------------------------------------------------------- -------------- ---------------------- ---------------------- ---------
  Total, n (%^[a](#tfn1-ol-0-0-4788){ref-type="table-fn"}^)             2,045          1,784 (87.2)           82 (4.0)               
  Age, years                                                                                                                         \<0.001
    Range                                                               25--94         31--94                 25--83                 
    Median                                                              64.0           64.4                   58.0                   
  Gender, n (%^[b](#tfn2-ol-0-0-4788){ref-type="table-fn"}^)                                                                         \<0.001
    Male                                                                1,420 (69.4)   1,262 (70.7)             31 (37.8)            
    Female                                                                605 (29.6)     507 (28.4)             49 (59.8)            
    Unknown                                                               20 (1.0)       15 (0.8)               2 (2.4)              
  Histology, n (%^[b](#tfn2-ol-0-0-4788){ref-type="table-fn"}^)                                                                      0.017
    Adenocarcinoma                                                      1,559 (76.2)   1,352 (75.8)             72 (87.8)            
    Squamous cell carcinoma                                               263 (12.9)     239 (13.4)             1 (1.2)              
    Large cell neuroendocrine carcinoma                                   21 (1.0)       18 (1.0)               2 (2.4)              
    Adenosquamous carcinoma                                               17 (0.8)       16 (0.9)               0 (0.0)              
    Not otherwise specified                                               185 (9.0)      159 (8.9)              7 (8.5)              
  Smoking history, n (%^[b](#tfn2-ol-0-0-4788){ref-type="table-fn"}^)                                                                \<0.001
    Ex-smoker                                                             783 (38.3)     688 (38.6)             20 (24.4)            
    Smoker                                                                761 (37.2)     661 (37.0)             23 (28.0)            
    Non-smoker                                                            372 (18.2)     312 (17.5)             34 (41.5)            
    Unknown                                                               129 (6.3)      123 (6.9)              5 (6.1)              
  Stage, n (%^[b](#tfn2-ol-0-0-4788){ref-type="table-fn"}^)                                                                          \<0.001
    T1 (T1a+T1b)                                                          36 (1.8)       34 (1.9)               1 (1.2)              
    T2                                                                    39 (1.9)       38 (2.1)               1 (1.2)              
    T3                                                                    126 (6.2)      117 (6.6)              3 (3.7)              
    T4                                                                    883 (43.2)     780 (43.7)             47 (57.3)            
    Unknown                                                               961 (47.0)     815 (45.7)             30 (36.6)            

Percentage of total patients

percentage by *ALK* rearrangement group. *ALK*, anaplastic lymphoma receptor tyrosine kinase.

###### 

Adenocarcinoma growth patterns of *ALK* gene rearrangement-positive patients (n=72).

  Pattern of growth                                                   Cases, n
  ------------------------------------------------------------------- ----------
  Solid adenocarcinoma NOS                                            19
  Solid with signet ring cells                                        12
  Acinar adenocarcinoma NOS                                           13
  Cribriform adenocarcinoma                                             2
  Colloid adenocarcinoma                                                4
  Mixed adenocarcinoma^[a](#tfn3-ol-0-0-4788){ref-type="table-fn"}^     5
  Adenocarcinoma NOS                                                    8
  Unknown                                                               9

Including solid-papillary patterns (1 case), solid-cribriform patterns (1 case), acinar-cribriform patterns (1 case), acinar-solid patterns (1 case), and acinar-micropapillary patterns (1 case). NOS, not otherwise specified; *ALK*, anaplastic lymphoma receptor tyrosine kinase.
